利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.013 秒)

    IDNA VACCINES AND METHODS FOR USING THE SAME
    2.
    发明公开
    IDNA VACCINES AND METHODS FOR USING THE SAME 审中-公开
    IDNA-IMPFSTOFFE UND VERFAHREN ZUR VERWENDUNG DAVON

    公开(公告)号：EP2977457A3

    公开(公告)日：2016-05-04

    申请号：EP15166439.8

    申请日：2009-07-17

    申请人： Medigen, Inc.

    发明人： PUSHKO, Peter ,  LUKASHEVICH, Igor

    IPC分类号： C12N15/65 ,  A61K48/00 ,  C12N5/00 ,  C12N15/85

    CPC分类号： A61K39/193 ,  A61K39/12 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/36134 ,  C12N2770/36161 ,  Y02A50/388

    摘要： Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

    摘要翻译： 本文描述的是iDNA载体和疫苗及其使用方法。 iDNA在真核细胞中在体外或体内产生致病性RNA病毒，特别是黄热病病毒和委内瑞兰马脑炎病毒的减毒疫苗。 当将iDNA注射到疫苗接受者中时，活体减毒病毒的RNA通过受体组织中的体内转录产生。 这启动了在疫苗接受者的组织中产生后代减毒病毒，以及引发保护免受野生型非减毒病毒的有效免疫应答。

    IDNA VACCINES AND METHODS FOR USING THE SAME
    3.
    发明公开
    IDNA VACCINES AND METHODS FOR USING THE SAME 审中-公开
    IDNA疫苗及其使用方法

    公开(公告)号：EP2977457A2

    公开(公告)日：2016-01-27

    申请号：EP15166439.8

    申请日：2009-07-17

    申请人： Medigen, Inc.

    发明人： PUSHKO, Peter ,  LUKASHEVICH, Igor

    IPC分类号： C12N15/65 ,  A61K48/00 ,  C12N5/00 ,  C12N15/85

    CPC分类号： A61K39/193 ,  A61K39/12 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/36134 ,  C12N2770/36161 ,  Y02A50/388

    摘要： Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

    摘要翻译： 本文描述了iDNA载体和疫苗以及使用它们的方法。 iDNA在体外或体内真核细胞中产生病毒RNA病毒，特别是黄热病病毒和委内瑞拉马脑炎病毒的减毒活疫苗。 当iDNA被注射到疫苗接受者体内时，活的减毒病毒的RNA通过在受体组织中的体内转录产生。 这启动了疫苗接受者组织中子代减毒病毒的产生，以及引发针对野生型非减毒病毒的有效免疫应答。

    MEMBRANE VIRUS HOST RANGE MUTATIONS AND THEIR USES AS VACCINE SUBSTRATES
    5.
    发明授权
    MEMBRANE VIRUS HOST RANGE MUTATIONS AND THEIR USES AS VACCINE SUBSTRATES 有权
    FOR A WITSSPEKTRUM病毒膜突变及其作为VAKZINSUBSTRAT

    公开(公告)号：EP1037603B1

    公开(公告)日：2006-11-22

    申请号：EP98947150.3

    申请日：1998-09-18

    申请人： RESEARCH DEVELOPMENT FOUNDATION

    发明人： BROWN, Dennis, T. ,  HERNANDEZ, Racquel

    IPC分类号： A61K39/12 ,  C07K14/18

    CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N2770/36122 ,  C12N2770/36161

    摘要： The vaccines and methods of the present invention are based on deletion mutations in the protein transmembrane domains of membrane-enveloped viruses. The strategy for production of these mutations is based on the fact that unlike mammalian cell membranes, the membranes of insect cells contain no cholesterol; thus are thinner than mammalian membranes. Many membrane-coated viruses have membrane glycoproteins on their surface which are responsible for identifying and infecting target cells. These membrane glycoproteins have hydrophobic membrane-spanning domains which anchor the proteins in the membrane bilayer. The membrane-spanning domains of these transmembrane proteins must be long enough to reach from one side of the bilayer to the other in order to hold the proteins in the membrane. Provided is a vaccine, a method of producing this vaccine, and a method of using this vaccine, based on the differences between membranes of viruses replicated in invertebrates and membranes of viruses replicated in vertebrates.